STAT3 and lung carcinoma: We have recently shown that gefitinib or osimertinib treatment results in the activation of not only STAT3, but also Src-YAP1 signaling, potentially operating downstream of IL-6, to promote cell survival and limit the initial response to EGFR TKI treatment in EGFR mutant lung cancer [23].